Kiadis Pharma (KIADF) Stock Price, News & Analysis

Company Overview

Kiadis Pharma N.V. was a Netherlands-based biopharmaceutical company focused on developing cell-based therapies for patients with life-threatening diseases. Its research centered on using immune cells to restore or enhance immune-system function, particularly in patients undergoing hematopoietic stem-cell transplantation.

The company’s leading investigational product was ATIR101, an allogeneic T-cell therapy designed for use following haploidentical stem-cell transplantation. Kiadis also pursued additional cell-therapy programs involving natural killer cells and other immune-cell approaches. These products were investigational and had not established broad commercial availability during the company’s independent operations.

Founded and headquartered in Amsterdam, Kiadis conducted development activities in Europe and North America. Sanofi acquired Kiadis in 2021, after which Kiadis ceased operating as an independent publicly traded biotechnology company. Arthur Lahr served as the company’s chief executive officer during its later independent period.

Key Stats

• Today's Range: $6.41 to $6.41
• 50-Day Range: $6.41 to $6.41
• 52-Week Range: $1.72 to $6.55
• Volume: N/A
• Average Volume: 1,800 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:KIADF
• CIK: N/A
• Web: www.kiadis.com
• Phone: 31 20 240 5250
• Fax: N/A
• Employees: 103
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A